Skip to main content
Caplight Logo









GeneCraft Inc.

GeneCraft Inc.

Private
Cheongju-siHealthcare & Life Scienceshttps://genecraft.co.kr/

Last Round

Series A

Jan 15, 2024

Total Funding Raised

$7.48M

Company Overview

GeneCraft Inc. is a biotechnology company that develops gene therapies for the treatment of cancer, specifically focusing on K-RAS mutated lung cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

gene therapyAAV vectoroncologyK-RAS mutationCRDOcontract researchbiotechgene deliveryvector engineeringdrug discoveryprecision medicinebiopharmaAI-driven biotechlung cancer therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GeneCraft Inc. Comparables

Compare GeneCraft Inc. with similar companies based on industry and business-model similarity.

GeneCraft Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Trogenix
75%
Vironexis Biotherapeutics
73%
Siren Biotechnology
71%

GeneCraft Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 15, 2024

Key People

Founding team and executive leadership

Hongseok Ji

Chief Executive Officer

Executive Team

GeneCraft Inc. Investors

Notable investors and investment history

GeneCraft Inc. investors
InvestorRounds
Infobank CorpSeries A
Seoul National University Technology HoldingsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 22, 2026

    Monthly visitors grew 316% MoM, from 331 to 1.4K.

  • Jun 18, 2024

    Grew 50% QoQ from 6 to 9 employees.

GeneCraft Inc. Filings

Explore SEC and related filing metadata, where available.

GeneCraft Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GeneCraft Inc.'s valuation, stock price, and market status.

Is GeneCraft Inc. a public or private company?

GeneCraft Inc. is a private company.

What is the current stock price of GeneCraft Inc.?

GeneCraft Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is GeneCraft Inc. worth (valuation)?

Valuation information for GeneCraft Inc. is not publicly available.

Can I buy GeneCraft Inc. stock?

GeneCraft Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GeneCraft Inc.'s last funding round?

GeneCraft Inc.'s most recent funding round was Series A on January 15, 2024.

Who are the main investors in GeneCraft Inc.?

Key investors in GeneCraft Inc. include Infobank Corp, Seoul National University Technology Holdings.

Will GeneCraft Inc. IPO soon?

No public IPO plans have been announced for GeneCraft Inc..

How can I track GeneCraft Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GeneCraft Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCheongju-si
Employee Range8
Year Founded2020
Last FundingJan 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?